S-1/A: Entero Therapeutics Files Amended Prospectus for $4 Million Offering Amidst Financial Distress and Strategic Restructuring

Entero Therapeutics, Inc. is seeking to raise approximately $4 million through a public offering of common stock and pre-funded warrants to fund operations and advance its lead drug candidate, Adrulipase, while navigating severe financial constraints and the rescission of a recent merger.

Summary

• Entero Therapeutics, Inc. (formerly First Wave Biopharma, Inc.) is offering 12,000,000 shares of common stock or pre-funded warrants to purchase 12,000,000 shares, with an estimated public offering price of $0.50 per share.
• The company expects to receive net proceeds of approximately $4,000,000 from this offering.
• Proceeds are intended to be used for up to $1,500,000 for marketing and advertising services, approximately $1,100,000 for repayment of outstanding liabilities (including $695,000 of ImmunogenX, LLC accounts payable), and approximately $1,400,000 to advance the Adrulipase program.
• The company has incurred significant operating losses and negative cash flows since inception, with an accumulated deficit of approximately $203.6 million as of March 31, 2025.
• Net losses were approximately $18.1 million for the year ended December 31, 2024, and $15.8 million for the year ended December 31, 2023.
• Cash and cash equivalents were approximately $66,000 as of March 31, 2025, and $0.2 million as of December 31, 2024.
• The company received a going concern qualification in its audits for the financial years ended December 31, 2024, and 2023.
• Entero Therapeutics is rescinding its merger with ImmunogenX, LLC, which was closed in March 2024, to focus solely on its Adrulipase program.
• As part of the rescission, Entero Therapeutics will retain up to approximately $695,000 of ImmunogenX, LLC's accounts payable, while ImmunogenX, LLC will remain responsible for approximately $2,436,338 of its secured debt.
• The rescission agreement's consummation deadline was mutually extended from June 30, 2025, to September 30, 2025, pending shareholder approval.
• The Adrulipase program, targeting exocrine pancreatic insufficiency (EPI) in cystic fibrosis and chronic pancreatitis patients, has seen approximately $7.01 million invested since fiscal year 2022.
• Phase 2b pilot monotherapy study for Adrulipase did not meet its primary efficacy endpoint (mean CFA 66% at 2240 mg/day, 53% at 4480 mg/day DR formulation; 52.9% and 50.6% for IR formulations), falling below the targeted 80% CFA.
• However, a Phase 2 combination therapy trial of Adrulipase with PERT showed clinically meaningful improvements in CFA (average gain >6 percentage points from baseline, with all patients achieving >80% CFA).
• The Latiglutenase, Capeserod, and Niclosamide programs have been discontinued due to capital constraints and strategic refocusing.
• The company has reduced its full-time employee headcount from 15 as of March 31, 2024, to 2 as of July 2, 2025, due to significant capital constraints.
• Entero Therapeutics faces ongoing Nasdaq listing compliance issues related to minimum stockholders' equity and minimum bid price, with extensions granted until October 8, 2025, and September 1, 2025, respectively.
• A lawsuit by Mattress Liquidators, Inc. against ImmunogenX, LLC and its guarantors (including Dr. Syage) for a $7.57 million loan default was settled, with Dr. Syage and his trust agreeing to pay $5.5 million and ImmunogenX, LLC retaining a $2.43 million revolving loan.
• The company is also facing a lawsuit from Ellenoff Grossman & Schole LLP for $749,301.00 in unpaid legal fees and is negotiating a settlement.

Sentiment

Score: 2

Explanation: The company is in severe financial distress, evidenced by recurring losses, a substantial accumulated deficit, and a going concern warning from auditors. While a strategic refocusing and capital raise are underway, the efficacy results for the lead drug's monotherapy were disappointing, and significant risks remain regarding funding, Nasdaq compliance, and contingent liabilities from the rescinded merger. The headcount reduction further underscores the dire financial situation.

Positives

• The company is undertaking a strategic refocusing to concentrate limited resources on its lead drug candidate, Adrulipase, by rescinding the ImmunogenX merger and discontinuing other programs.
• The rescission of the ImmunogenX merger is expected to eliminate significant secured debt obligations and contingent liabilities associated with the acquisition, improving the balance sheet and financial flexibility.
• The Adrulipase program has received substantial historical investment of approximately $7.01 million since fiscal year 2022, indicating a valuable clinical and intellectual property foundation.
• Positive topline data from the Phase 2 Combination Trial of Adrulipase with PERT showed clinically meaningful improvements in Coefficient of Fat Absorption (CFA), meeting the primary efficacy endpoint with all patients achieving CFAs greater than 80%.
• Adrulipase addresses a significant unmet medical need in well-defined patient populations, with an estimated 40,000 people in the U.S. suffering from EPI due to cystic fibrosis and 300,000-500,000 patients with EPI due to chronic pancreatitis.
• The company has secured a $2.0 million revolving loan agreement in January 2025, providing some liquidity.
• The lawsuit with Mattress Liquidators, Inc. has been settled, with the majority of the debt assumed by Dr. Syage and his trust, reducing the company's direct liability if the rescission is consummated.

Negatives

• The company has incurred significant operating losses and negative cash flows from operations since inception, with an accumulated deficit of approximately $203.6 million as of March 31, 2025.
• Auditors have issued a going concern qualification for the financial years ended December 31, 2024, and 2023, indicating substantial doubt about the company's ability to continue operations.
• Cash and cash equivalents were critically low at approximately $66,000 as of March 31, 2025.
• The Phase 2b pilot monotherapy study for Adrulipase did not meet its primary efficacy endpoint, with mean CFAs significantly below the targeted therapeutic threshold of 80%.
• The Latiglutenase program, which was the focus of the ImmunogenX merger, was discontinued due to insufficient efficacy for FDA approval and high capital requirements ($30 million estimated for Phase 3) with high execution risk.
• The company has drastically reduced its full-time employee headcount from 15 to 2 due to significant capital constraints.
• The company is dependent on obtaining additional working capital funding from the sale of equity and/or debt securities, with no guarantee of success or acceptable terms.
• If the ImmunogenX merger rescission is not consummated, the company will be liable for approximately $2,436,338 of ImmunogenX, LLC's secured debt and an additional $46,000 of accounts payable, which it does not expect to have funds to cover.
• The company faces a lawsuit for $749,301.00 in unpaid legal fees from Ellenoff Grossman & Schole LLP.
• The company is not in compliance with Nasdaq's minimum stockholders' equity requirement (deficit of $3.87 million vs. $2.5 million required) and minimum bid price requirement ($1.00), risking delisting.
• New investors in this offering will experience immediate and substantial dilution of $0.46 per share.

Risks

• Substantial doubt about the company's ability to continue as a going concern due to significant operating losses, negative cash flows, and dependence on external funding.
• Failure to obtain necessary additional financing could force the company to delay, limit, reduce, or terminate product development programs, commercialization efforts, or other operations.
• If the ImmunogenX merger rescission is not consummated, the company will be liable for approximately $2,436,338 of ImmunogenX, LLC's secured debt and an additional $46,000 of its accounts payable, potentially leading to further litigation and adverse impact on financial condition.
• The company's failure to maintain compliance with Nasdaq's continued listing requirements (minimum stockholders' equity, minimum bid price) could result in delisting of its common stock, adversely affecting liquidity and ability to raise capital.
• Future sales of common stock could lower the stock price and dilute existing stockholders.
• The Pre-funded Warrants will not be listed or quoted on any exchange, limiting their liquidity.
• Holders of Pre-funded Warrants will have no rights as stockholders until such warrants are exercised.
• The company's management will have broad discretion over the use of net proceeds from the offering, which may not increase operating results or market value.
• The Adrulipase program's Phase 2b monotherapy trial did not meet its primary efficacy endpoint, indicating potential challenges in future clinical development.
• The company may incur significant losses in the future due to unforeseen expenses, difficulties, complications, delays, and other unknown events, making it harder to achieve or maintain profitability.
• The company's intellectual property protection may not afford complete protection against competitors, and reliance on trade secret protection and confidentiality agreements may not be sufficient.

Future Outlook

The company anticipates having sufficient cash to fund planned operations through April 2026, assuming successful financing efforts from this offering and the closing of the Rescission Agreement. However, if the rescission is not consummated, funds are only expected to last for at least six months. The company plans to seek follow-on financing by the end of the third quarter of 2025, specifically to fund Phase 3 clinical trials for Adrulipase. They are planning to move the Adrulipase program forward in 2025, including initiating a Phase 2b clinical trial in the second half of 2025.

Management Comments

• Management believes the strategic refocusing on Adrulipase is supported by multiple business and financial considerations, including the elimination of secured debt obligations and resource allocation constraints.
• Management views Adrulipase as the company's most valuable asset in its patent portfolio and intends to streamline its patent portfolio on gut-restricted gastrointestinal clinical drug candidates.
• Management believes that the underlying cause of Adrulipase's uneven performance in the OPTION 2 trial was the enteric capsule formulation, which appeared to dissolve too slowly.
• Management believes that additional capital will be needed to begin a Phase 3 clinical trial for Adrulipase, beyond the proceeds from this offering.
• Management will have broad discretion in the application of the net proceeds from this offering.

Industry Context

Entero Therapeutics operates in the biopharmaceutical industry, specifically focusing on non-systemic therapies for gastrointestinal (GI) diseases. Its primary focus on Adrulipase for Exocrine Pancreatic Insufficiency (EPI) positions it within the pancreatic enzyme replacement therapy (PERT) market, which is well-established with estimated sales of approximately $2.1 billion in the U.S. in 2024 and a compound annual growth rate of approximately 20% over the past five years. The company aims to offer a non-animal derived alternative to current porcine-derived PERTs, addressing issues like stability, formulation, and potential transmission of infectious agents. The strategic shift away from celiac disease (Latiglutenase) and inflammatory bowel diseases (Niclosamide) to concentrate on EPI reflects a common industry trend of narrowing focus for capital-constrained biotechs to their most promising or advanced assets with clearer regulatory pathways and larger patient populations.

Comparison to Industry Standards

• Current treatments for EPI, primarily porcine-derived pancreatic enzyme replacement therapies (PERTs), have estimated sales of approximately $2.1 billion in the U.S. in 2024, growing at a 20% CAGR over the past five years. Adrulipase aims to compete in this market by offering a non-animal derived alternative.
• The Phase 2b pilot monotherapy study for Adrulipase showed mean Coefficient of Fat Absorption (CFA) of 66% (2240 mg/day DR) and 53% (4480 mg/day DR), and 52.9% (4.4 grams/day IR) and 50.6% (6.6 grams/day IR), which were below the targeted CFA of greater than or equal to 80% generally considered indicative of adequate fat absorption. This compares unfavorably to standard porcine PERT, which achieved mean CFAs of approximately 86% in previous comparator trials (e.g., Study AZ-CF2001).
• In contrast, the Phase 2 Combination Trial of Adrulipase with PERT demonstrated clinically meaningful improvements in CFA, with patients showing an average gain of more than six percentage points from baseline, exceeding the five-point improvement cited by clinical literature as clinically significant, and all patients achieving CFAs greater than 80%. This suggests a potential role for Adrulipase as an adjunct therapy.
• The Latiglutenase program, which required an estimated $30 million for Phase 3 trials, faced insufficient efficacy for FDA approval, with a 2022 study finding no statistically significant improvement in serology markers compared to placebo, highlighting the high risk and capital intensity of drug development, especially for assets with mixed efficacy signals.

Management Changes

Corporate Governance

Legal Proceedings

• Mattress Liquidators, Inc. filed a complaint on December 31, 2024, against ImmunogenX, LLC, Dr. Jack A. Syage, and The Jack A. Syage and Elizabeth T. Syage Revocable Trust for alleged breach of a Credit Agreement totaling $7,575,568.91.
• A Settlement Agreement was reached effective April 9, 2025, where Dr. Syage and his trust agreed to pay $5,500,000 of the obligations, and ImmunogenX, LLC retained a revolving loan of $2,436,338.30. The plaintiff agreed to release its security interest, and a Stipulation of Dismissal with Prejudice is to be filed.
• Ellenoff Grossman & Schole LLP filed a lawsuit on March 17, 2025, against the company in New York, seeking $749,301.00 for unpaid legal fees, costs, and disbursements. The company is evaluating claims and negotiating a settlement.

Related Party Transactions

• Dr. Jack Syage, a director and Chief Scientific Officer of the company, was a principal of ImmunogenX, Inc. and a party to the Credit Agreement and subsequent Settlement Agreement with Mattress Liquidators, Inc., where he and his trust agreed to pay $5.5 million of the debt.
• Dr. Syage, as the representative of IMGX Shareholders, mutually agreed with the company to extend the consummation date of the Rescission Agreement to September 30, 2025.
• Following consummation of the Rescission Agreement, Dr. Jack Syage and his affiliated entities will own approximately 42% of the transferred membership interests of ImmunogenX, LLC.
• The company is in discussions with unsecured creditors of ImmunogenX, LLC, including Dr. Jack Syage and Peter Felker (each holding unsecured promissory notes at 13% maturing September 30, 2025), to negotiate partial repayment in exchange for complete release of liabilities.

Stakeholder Impact

• **Shareholders**: Face significant dilution from the current offering and potential future capital raises. Existing shareholders have experienced substantial dilution and negative net tangible book value. The ongoing Nasdaq compliance issues pose a risk of delisting, which would severely impact liquidity and the value of their investment. The strategic refocusing on Adrulipase aims to create long-term value, but the high risks and financial instability remain a major concern.
• **Employees**: The company has significantly reduced its full-time employee headcount from 15 to 2 due to capital constraints, indicating job insecurity and a highly lean operational structure.
• **Creditors**: The company has substantial outstanding liabilities and is negotiating with vendors and unsecured creditors for partial repayment. The rescission of the ImmunogenX merger aims to reduce the company's direct liability for a significant secured debt, but if it fails, the company would be liable for over $2.4 million in secured debt and additional accounts payable, potentially leading to further legal action.
• **Customers/Patients (future)**: The strategic focus on Adrulipase aims to bring a non-animal derived therapy for EPI to market, potentially offering a new treatment option for patients with cystic fibrosis and chronic pancreatitis, addressing unmet medical needs and pill burden associated with current PERTs.

Next Steps

• Consummate the Rescission Agreement with ImmunogenX, LLC on or prior to September 30, 2025, subject to obtaining shareholder approval.
• Use net proceeds from the current offering to fund operations for at least 10 months (or 6 months if rescission fails), including marketing, liability repayment, and advancing Adrulipase development.
• Plan a meeting with the FDA to discuss next steps for the Adrulipase monotherapy program.
• Initiate a Phase 2b clinical trial for Adrulipase in the second half of 2025.
• Seek follow-on financing by the end of the third quarter of 2025 to fund Phase 3 trials for Adrulipase.
• Regain and maintain compliance with Nasdaq's minimum stockholders' equity requirement by October 8, 2025.
• Regain and maintain compliance with Nasdaq's minimum bid price requirement by September 1, 2025.
• Continue evaluating claims and negotiating settlement with Ellenoff Grossman & Schole LLP regarding unpaid legal fees.

Key Dates

Recommendation

Keywords

Biopharmaceutical, Gastrointestinal diseases, Exocrine pancreatic insufficiency, Cystic fibrosis, Chronic pancreatitis, Adrulipase, Drug development, SEC filing, S-1/A, Public offering, Pre-funded warrants, Going concern, Nasdaq compliance, Merger rescission, Clinical trials, Financial distress, Biotech, Pharmaceuticals